勘误：评论：来自人胃的 属菌株的益生菌特性和技术特性，以寻找对抗胃微生物群失调的潜在候选菌株。 （注：原文中“ spp.”部分内容缺失，无法准确完整翻译这部分）
Corrigendum: Commentary: Probiotic and technological properties of spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis.
作者信息
Tyagi Amit K, Prasad Sahdeo
机构信息
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
Front Microbiol. 2019 Jul 18;10:1628. doi: 10.3389/fmicb.2019.01628. eCollection 2019.
Abstract
[This corrects the article DOI: 10.3389/fmicb.2015.00433.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fmicb.2015.00433。]
相似文献
1
Corrigendum: Commentary: Probiotic and technological properties of spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis.勘误：评论：来自人胃的 属菌株的益生菌特性和技术特性，以寻找对抗胃微生物群失调的潜在候选菌株。 （注：原文中“ spp.”部分内容缺失，无法准确完整翻译这部分）
Front Microbiol. 2019 Jul 18;10:1628. doi: 10.3389/fmicb.2019.01628. eCollection 2019.
2
Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis.述评：人胃中乳酸杆菌属菌株的益生菌特性及技术特性，以寻找对抗胃微生物群落失调的潜在候选菌株。
Front Microbiol. 2015 May 19;6:433. doi: 10.3389/fmicb.2015.00433. eCollection 2015.
3
Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis.从人胃中分离的乳酸杆菌属菌株的益生菌特性及技术特性，以寻找对抗胃微生物群落失调的潜在候选菌株。
Front Microbiol. 2015 Jan 14;5:766. doi: 10.3389/fmicb.2014.00766. eCollection 2014.
4
Are probiotics useful for therapy of Helicobacter pylori diseases?益生菌对幽门螺杆菌病的治疗有用吗？
Comp Immunol Microbiol Infect Dis. 2019 Jun;64:99-108. doi: 10.1016/j.cimid.2019.02.010. Epub 2019 Mar 5.
5
Probiotic spp. act Against -induced Inflammation.益生菌属对抗诱导性炎症。
J Clin Med. 2019 Jan 14;8(1):90. doi: 10.3390/jcm8010090.
6
Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis.补充益生菌的三联疗法根除儿童幽门螺杆菌的疗效和安全性：一项系统评价和网状Meta分析
Eur J Clin Pharmacol. 2017 Oct;73(10):1199-1208. doi: 10.1007/s00228-017-2291-6. Epub 2017 Jul 5.
7
Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection.幽门螺杆菌感染背景下胃源植物乳杆菌XB7的抗炎特性
Helicobacter. 2014 Apr;19(2):144-55. doi: 10.1111/hel.12105. Epub 2014 Jan 5.
8
Corrigendum: Diversity recovery and probiotic shift of gastric microbiota in functional dyspepsia patients after eradication therapy.勘误：根除治疗后功能性消化不良患者胃微生物群的多样性恢复和益生菌转变
Front Microbiol. 2024 Jan 8;14:1354558. doi: 10.3389/fmicb.2023.1354558. eCollection 2023.
9
Low co-existence rates of Lactobacillus spp. and Helicobacter pylori detected in gastric biopsies from patients with gastrointestinal symptoms.在有胃肠道症状患者的胃活检样本中检测到的乳酸杆菌属和幽门螺杆菌的共存率较低。
Rev Esp Enferm Dig. 2012 Sep;104(9):473-8. doi: 10.4321/s1130-01082012000900005.
10
Probiotic properties of Lactobacillus strains isolated from the feces of breast-fed infants and Taiwanese pickled cabbage.从母乳喂养婴儿的粪便和台湾酸菜中分离出的乳酸菌的益生菌特性。
Anaerobe. 2010 Dec;16(6):578-85. doi: 10.1016/j.anaerobe.2010.10.003. Epub 2010 Oct 15.
引用本文的文献
1
Assessment of beneficial effects and identification of host adaptation-associated genes of Ligilactobacillus salivarius isolated from badgers.评估来自獾的唾液乳杆菌的有益效果，并鉴定与宿主适应性相关的基因。
BMC Genomics. 2023 Sep 7;24(1):530. doi: 10.1186/s12864-023-09623-8.
本文引用的文献
1
Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial.罗伊氏乳杆菌治疗消化不良患者幽门螺杆菌感染的双盲安慰剂对照随机临床试验。
Therap Adv Gastroenterol. 2014 Jan;7(1):4-13. doi: 10.1177/1756283X13503514.
2
Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.罗伊氏乳杆菌菌株组合治疗幽门螺杆菌感染：一项随机、双盲、安慰剂对照研究。
J Clin Gastroenterol. 2014 May-Jun;48(5):407-13. doi: 10.1097/MCG.0000000000000007.
3
Lactobacillus reuteri in the treatment of Helicobacter pylori infection.罗伊氏乳杆菌治疗幽门螺杆菌感染
Intern Emerg Med. 2014 Sep;9(6):649-54. doi: 10.1007/s11739-013-1013-z. Epub 2013 Nov 1.
4
Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation.幽门螺杆菌根除：序贯疗法和罗伊氏乳杆菌补充。
World J Gastroenterol. 2012 Nov 21;18(43):6250-4. doi: 10.3748/wjg.v18.i43.6250.
5
Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone.三联疗法加乳铁蛋白和益生菌与三联疗法单独治疗比较在儿科患者中对幽门螺杆菌根除的评价。
Ital J Pediatr. 2012 Oct 31;38:63. doi: 10.1186/1824-7288-38-63.
6
Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy.鼠李糖乳杆菌补充剂对基于左氧氟沙星的抗幽门螺杆菌二线治疗的影响。
Gastroenterol Res Pract. 2012;2012:740381. doi: 10.1155/2012/740381. Epub 2012 May 29.
7
Triple therapies plus different probiotics for Helicobacter pylori eradication.三联疗法加不同益生菌用于根除幽门螺杆菌
Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):251-6.
8
Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study.罗伊氏乳杆菌ATCC 55730对人类幽门螺杆菌感染的抑制作用及其对根除治疗的影响：一项初步研究。
Helicobacter. 2008 Apr;13(2):127-34. doi: 10.1111/j.1523-5378.2008.00593.x.
9
Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study.罗伊氏乳杆菌片抑制幽门螺杆菌感染——一项双盲随机安慰剂对照交叉临床研究。
Kansenshogaku Zasshi. 2007 Jul;81(4):387-93. doi: 10.11150/kansenshogakuzasshi1970.81.387.
10
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial.罗伊氏乳杆菌疗法减轻儿童抗幽门螺杆菌治疗期间的副作用：一项随机安慰剂对照试验
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1461-8. doi: 10.1111/j.1365-2036.2006.03145.x. Epub 2006 Oct 10.
Zotero 插件